United States

Aeolus Pharmaceuticals Inc (AOLS.PK)

AOLS.PK on OTC Markets Group

Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Aeolus announces Q2 loss per share $0.01
Monday, 15 May 2017 05:00pm EDT 

May 15 (Reuters) - Aeolus Pharmaceuticals Inc :Aeolus announces second quarter financial results for fiscal year 2017.Q2 loss per share $0.01.Q2 revenue $129,000 versus $565,000.  Full Article

Aeolus Announces $6.75 Million Private Placement Financing
Tuesday, 15 Dec 2015 03:22pm EST 

Aeolus Pharmaceuticals, Inc:entered into definitive agreements with certain institutional and other accredited investors to raise gross proceeds of $6.75 million in a private placement financing.Net proceeds from this offering will be used for general corporate and working capital purposes, including the development of AEOL10150 as a medical countermeasure for pulmonary effects of acute radiation syndrome.In addition, the Company intends to use proceeds to pursue human clinical trials with AEOL 10150 in Idiopathic Pulmonary Fibrosis and radiation oncology and completion of pre-clinical development of AEOL 20415 for infectious diseases and AEOL 11114B for Parkinson's disease.Pursuant to purchase agreement, BVF will purchase $4.5 million of Preferred Units consisting of 4,500 shares of Series C Convertible Preferred Stock of the Company that are collectively convertible into an aggregate of 20,454,546 Common Shares and Warrants.Laidlaw & Company served as the placement agent for the offering.  Full Article

More From Around the Web

BRIEF-Aeolus announces Q2 loss per share $0.01

* Aeolus announces second quarter financial results for fiscal year 2017